Scott Tykodi, MD, PhD

University of Washington and Fred Hutchinson Cancer Center

Associate Professor of Medicine at the University of Washington School of Medicine and Fred Hutchinson Cancer Center in Seattle, Washington, where he is a member of the Kidney Cancer and Melanoma Program.

Published Articles (1)

Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise

May 29, 2026

Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.